echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yang Sen submits an application for HIV therapy rilpivirin injection in China

    Yang Sen submits an application for HIV therapy rilpivirin injection in China

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ArticleMedicine Guanlan

    Today (November 4), the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that Janssen, a subsidiary of Johnson & Johnson, has submitted a listing application for the new AIDS drug, Ripivirin injection, and Get accepted


    Screenshot source: CDE official website

    According to an early press release issued by Janssen, Rilpivirin is a small (25 mg) oral non-nucleoside reverse transcriptase inhibitor (NNRTI), which has the characteristics of definite efficacy, safety and well tolerability


    It is worth mentioning that the researchers also explored the "cocktail therapy" composed of ripavirin and other HIV therapies, and many of them have received regulatory approval


    Among them, Cabenuva is an injection preparation composed of ripavirin and cabotegravir


    According to the CDE announcement, the injection formulation of Ripavirin was submitted by Janssen Company this time


    Reference materials:

    [1] Drug Evaluation Center of China National Medical Products Administration.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.